Santiago Mendez-Huergo, PhD

Regeneron Pharmaceuticals, Inc.
Tarrytown, United States

Disclosure information not submitted.

Presentation(s):

• ORF18-05 - A Novel TSHR Blocking Antibody Effectively Reduces Hyperthyroidism and Proptosis in a Mouse Model of Graves' and Thyroid Eye Disease

  Saturday, June 13, 2026
  4:00 PM - 4:15 PM CT

• SUN-397 - In-Vitro Properties of REGN24493, A Novel TSHR Blocking Mab for the Treatment of Graves' Disease and Thyroid Eye Disease

  Sunday, June 14, 2026
  12:00 PM - 1:30 PM CT

• SUN-397 - In-Vitro Properties of REGN24493, A Novel TSHR Blocking Mab for the Treatment of Graves' Disease and Thyroid Eye Disease

  Sunday, June 14, 2026
  9:00 AM - 4:00 PM CT